Volume 11, Issue 6 (November & December 2020)
BCN 2020, 11(6): 855-860 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Esmaeili S, Shojaei S F, Bahadori M, Mojtahed M, Mehrpour M. Intravenous Thrombolysis for Acute Ischemic Stroke Due to Cardiac Myxoma. BCN 2020; 11 (6) :855-860
URL: http://bcn.iums.ac.ir/article-1-1494-en.html
URL: http://bcn.iums.ac.ir/article-1-1494-en.html
Sara Esmaeili1 
, Seyedeh Fahimeh Shojaei2 , Maryam Bahadori3 , Mohammad Mojtahed3 , Masoud Mehrpour * 4
, Seyedeh Fahimeh Shojaei2 , Maryam Bahadori3 , Mohammad Mojtahed3 , Masoud Mehrpour * 4
1- Department of Neurology, Cellular and Molecular Research Center, Firoozgar Hospital, Student Research Committee, Iran University of Medical Sciences, Tehran, Iran.
2- Firoozgar Clinical Research and Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
3- Department of Neurology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
4- Department of Neurology, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
2- Firoozgar Clinical Research and Development Center (FCRDC), Iran University of Medical Sciences, Tehran, Iran.
3- Department of Neurology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
4- Department of Neurology, School of Medicine, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Abstract:
Background: Myxoma may cause systemic embolization and frequently presents as ischemic stroke.
Case Presentation: There have been debates about whether it is safe to use recombinant tissue plasminogen activator (rt-PA) in patients with cardiac myxoma who referred with ischemic stroke to the hospital's emergency.
Results: The patient was a young case of atrial myxoma with initial presentation of acute cerebral infarction symptoms who was treated with intravenous rt-PA with no complications.
Conclusion: The case provides an evidence of the efficacy and safety of intravenous rt-PA in cases of cardiac myxoma. However, we cannot always expect thrombolytic therapy to be effective, especially in tumor emboli.
Case Presentation: There have been debates about whether it is safe to use recombinant tissue plasminogen activator (rt-PA) in patients with cardiac myxoma who referred with ischemic stroke to the hospital's emergency.
Results: The patient was a young case of atrial myxoma with initial presentation of acute cerebral infarction symptoms who was treated with intravenous rt-PA with no complications.
Conclusion: The case provides an evidence of the efficacy and safety of intravenous rt-PA in cases of cardiac myxoma. However, we cannot always expect thrombolytic therapy to be effective, especially in tumor emboli.
Type of Study: News and Reports |
Subject:
Clinical Neuroscience
Received: 2019/05/8 | Accepted: 2020/02/10 | Published: 2020/11/1
Received: 2019/05/8 | Accepted: 2020/02/10 | Published: 2020/11/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
